share_log

iBio Inc | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ADAR1 Capital Management, LLC(9.99%),ADAR1 Capital Management GP, LLC(9.99%), etc.

iBio Inc | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ADAR1 Capital Management, LLC(9.99%),ADAR1 Capital Management GP, LLC(9.99%), etc.

iBio Inc | SC 13G/A：超过5%持股股东披露文件(修正)-ADAR1 Capital Management, LLC(9.99%),ADAR1 Capital Management GP, LLC(9.99%)等
美股SEC公告 ·  2024/11/14 13:52

Moomoo AI 已提取核心信息

On November 14, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G/A filing with the United States Securities and Exchange Commission. The filing indicated that ADAR1 Capital Management, LLC, along with ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, collectively reported shared voting and dispositive power over 966,298 shares of iBio Inc's common stock, representing 9.99% of the company's class. The shares include common stock and shares underlying pre-funded and milestone warrants held by ADAR1 Partners, LP, with certain ownership limitations in place. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was jointly signed by Daniel Schneeberger, who may be deemed to indirectly beneficially own the securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
On November 14, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G/A filing with the United States Securities and Exchange Commission. The filing indicated that ADAR1 Capital Management, LLC, along with ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, collectively reported shared voting and dispositive power over 966,298 shares of iBio Inc's common stock, representing 9.99% of the company's class. The shares include common stock and shares underlying pre-funded and milestone warrants held by ADAR1 Partners, LP, with certain ownership limitations in place. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was jointly signed by Daniel Schneeberger, who may be deemed to indirectly beneficially own the securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
在2024年11月14日，生物技术公司ibio inc向美国证券交易委员会提交了一份Schedule 13G/A文件。该文件显示，ADAR1 Capital Management, LLC及其子公司ADAR1 Capital Management GP, LLC和Daniel Schneeberger共同报告对ibio inc的966,298股普通股（占公司类别的9.99%）拥有共享投票权和处置权。这些股份包括普通股和ADAR1 Partners, LP持有的预融资和里程碑warrants所对应的股份，但存在一定的所有权限制。该文件依据1934年证券交易法第13d-1(b)条款提交，表明这些股...展开全部
在2024年11月14日，生物技术公司ibio inc向美国证券交易委员会提交了一份Schedule 13G/A文件。该文件显示，ADAR1 Capital Management, LLC及其子公司ADAR1 Capital Management GP, LLC和Daniel Schneeberger共同报告对ibio inc的966,298股普通股（占公司类别的9.99%）拥有共享投票权和处置权。这些股份包括普通股和ADAR1 Partners, LP持有的预融资和里程碑warrants所对应的股份，但存在一定的所有权限制。该文件依据1934年证券交易法第13d-1(b)条款提交，表明这些股份是在正常业务过程中获得的，并非为了改变或影响ibio inc的控制权。报告人的主要业务办公室位于德克萨斯州奥斯汀，文件由Daniel Schneeberger联合签署，他可能被视为间接受益于ADAR1 Partners, LP和Spearhead Insurance Solutions IDF, LLC持有的证券。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！